Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP).

Blood (2007) 110 (11): 2014.

https://doi.org/10.1182/blood.V110.11.2014.2014

Published: 2007

Journal Articles

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS.

B. Oran, R. Saliba, S. Giralt, D. Couriel, A. Carrasco-Yalan, C. Hosing, M. Shahjahan, E. de Meis, A. Anagnostopoulos, P. Anderlini, S. Ghosh, I. Khouri, R. Champlin, M. de Lima

Blood (2005) 106 (11): 838.

https://doi.org/10.1182/blood.V106.11.838.838

Published: 2005

Journal Articles

Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

Marcos de Lima, S. Giralt, Z. Caldera, G. McCormick, M. Qazilbash, P. Anderlini, E. J. Shpall, C. Hosing, M. Donato, S. Kornblau, I. Khouri, T. Martin, D. Couriel, R. Champlin

Blood (2005) 106 (11): 841.

https://doi.org/10.1182/blood.V106.11.841.841

Published: 2005

Journal Articles

Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

D. Przepiorka, N. A. Kernan, C. Ippoliti, E. B. Papadopoulos, S. Giralt, I. Khouri, J.-G. Lu, J. Gajewski, A. Durett, K. Cleary, R. Champlin, B. S. Andersson, S. Light

Blood (2000) 95 (1): 83–89.

https://doi.org/10.1182/blood.V95.1.83

Published: 2000

Journal Articles

Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation

D Przepiorka, C Ippoliti, I Khouri, M Woo, R Mehra, D Le Bherz, S Giralt, J Gajewski, H Fischer, H Fritsche, AB Deisseroth, K Cleary, R Champlin, K Besien, B Andersson, R Maher, W Fitzsimmons

Blood (1996) 88 (11): 4383–4389.

https://doi.org/10.1182/blood.V88.11.4383.4383

Published: 1996

Journal Articles

CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation

S Giralt, J Hester, Y Huh, C Hirsch-Ginsberg, G Rondon, D Seong, M Lee, J Gajewski, K Van Besien, I Khouri

Blood (1995) 86 (11): 4337–4343.

https://doi.org/10.1182/blood.V86.11.4337.bloodjournal86114337

Published: 1995

Journal Articles

Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional- dose chemotherapy before collection of autologous cells

M Talpaz, H Kantarjian, J Liang, L Calvert, J Hamer, P Tibbits, A Durett, D Claxton, S Giralt, I Khouri

Blood (1995) 85 (11): 3257–3263.

https://doi.org/10.1182/blood.V85.11.3257.bloodjournal85113257

Published: 1995

NARROW

Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP).

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS.

Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation

CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation

Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional- dose chemotherapy before collection of autologous cells

Email alerts

ASH Publications

American Society of Hematology

Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP).

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS.

Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation

CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation

Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional- dose chemotherapy before collection of autologous cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only